Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.41M$12.41Mderived+22.5% vs Q4 2023 Net Income$1.88M$1.88Mderived+76.3% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$7,906,000+25.2% Operating Incomederived$2,061,000+38.3% Operating Cash Flowderived$1,184,000+3.9% Free Cash Flowderived$1,055,000+5.7% Margins · derivedGross margin63.7%+1.4 pt vs Q4 2023
Operating margin16.6%+1.9 pt vs Q4 2023
Net margin15.2%+4.6 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end